Metformin inhibits proliferation of human keratinocytes through a mechanism associated with activation of the MAPK signaling pathway

Experimental and Therapeutic Medicine

Volumn 7, Issue 2, 2014, Pages 389-392

  Li, Weining ^a,b   Ma, Weiyuan ^a   Zhong, Hua ^a   Liu, Wenbin ^a   Sun, Qing ^a  

^a SHANDONG UNIVERSITY   (China)

^b AFFILIATED HOSPITAL OF SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Adenosine monophosphate activated protein kinase; Extracellular signal related kinase 1 2; HaCaT cells; Metformin; Proliferation; Psoriasis

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; KERATINOCYTE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL RATE; WESTERN BLOTTING;

EID: 84890474968     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1416     Document Type: Article

References (22)

1. Vestergaard C, Deleuran M, Gesser B and Grønhøj Larsen C: Expression of the T-helper 2-specific chemokine receptor CCR4 on CCR10-positive lymphocytes in atopic dermatitis skin but not in psoriasis skin. Br J Dermato1 149: 457-463, 2003.
2. Bowcock AM and Krueger JG: Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 5: 699-711, 2005.
3. Bhalerao J and Bowcock AM: The genetics of psoriasis: a complex disorder of the skin and immune system. Hum Mol Genet 7: 1537-1545, 1998.
4. Bowcock AM and Cookson WO: The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet 13: R43-R55, 2004.
5. Abdou AG and Hanout HM: Evaluation of survivin and NF-kappaB in psoriasis, an immunohistochemical study. J Cutan Pathol 35: 445-451, 2008.
6. Rahman M, Alam K, Ahmad MZ, et al: Classical to current approach for treatment of psoriasis: a review. Endocr Metab Immune Disord Drug Targets 12: 287-302, 2012.
7. Fusenig NE and Boukamp P: Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Mol Carcinog 23: 144-158, 1998.
8. Stein M, Bernd A, Ramirez-Bosca A, Kippenberger S and Holzmann H: Measurement of anti-inflammatory effects of glucocorticoids on human keratinocytes in vitro. Comparison of normal human keratinocytes with the keratinocyte cell line HaCaT. Arzneimittelforschung 47: 1266-1270, 1997.
9. Müller K and Prinz H: Antipsoriatic anthrones with modulated redox properties. 4. Synthesis and biological activity of novel 9, 10-dihydro-1,8-dihydroxy-9-oxo-2-anthracenecarboxylic and -hydroxamic acids. J Med Chem 40: 2780-2787, 1997.
10. Kahn BB, Alquier T, Caning D and Hardie DG: AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15-25, 2005.
11. Witters LA: The blooming of the French lilac. J Clin Invest 108: 1105-1107, 2001.
12. Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q and Kip KE: Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 97: 2347-2353, 2012.
13. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B and Thompson CB: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67: 6745-6752, 2007.
14. Ben Sahra I, Laurent K, Loubat A, et al: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27: 3576-3586, 2008.
15. Dowling RJ, Zakikhani M, Fantus IG, Pollak M and Sonenberg N: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67: 10804-10812, 2007.
16. Rattan R, Giri S, Hattmann L and Shridhar V: Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med 15: 166-178, 2011.
17. Zakikhani M, Dowling R, Fantus IG, Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10269-10273, 2006.
18. Bosch M, Gil J, Bachs O and Agell N: Calmodulin inhibitor W13 induces sustained activation of ERK2 and expression of p21(cip1). J Biol Chem 273: 22145-22150, 1998.
19. Wang H, Zeng Y, Ji Y and Xing F: Two-sided effect of ERK signal pathway on HaCaT cell proliferation induced by EGF. Basic & Clinical Medicine 26: 471-475, 2006 (In Chinese).
20. Pumiglia KM and Decker SJ: Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc Natl Acad Sci USA 94: 448-452, 1997.
21. Wang Z, Zhang B, Wang M and Carr BI: Persistent ERK phosphorylation negatively regulates cAMP response element-binding (CREB) activity via recruitment of CREB-binding protein to pp90RSK. J Biol Chem 278: 11138-11144, 2003.
22. Tang D, Wu D, Hirao A, et al: ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem 277: 12710-12717, 2002.